Michael C Gold1, Shiwen Yuan1, Eric Tirrell2, E Frances Kronenberg2, Jee Won D Kang2, Lauren Hindley2, Mohamed Sherif3, Joshua C Brown1, Linda L Carpenter4. 1. Butler Hospital TMS Clinic and Neuromodulation Research Facility, Providence, RI, USA; Department of Psychiatry and Human Behavior, Alpert Medical School, Brown University, USA. 2. Butler Hospital TMS Clinic and Neuromodulation Research Facility, Providence, RI, USA. 3. Department of Psychiatry and Human Behavior, Alpert Medical School, Brown University, USA; Lifespan Physician Group, Rhode Island Hospital, Providence, RI, USA. 4. Butler Hospital TMS Clinic and Neuromodulation Research Facility, Providence, RI, USA; Department of Psychiatry and Human Behavior, Alpert Medical School, Brown University, USA. Electronic address: linda_carpenter_md@brown.edu.
Abstract
BACKGROUND: Transcranial magnetic stimulation (TMS) is an effective therapy for patients with treatment-resistant depression. TMS likely induces functional connectivity changes in aberrant circuits implicated in depression. Electroencephalography (EEG) "microstates" are topographies hypothesized to represent large-scale resting networks. Canonical microstates have recently been proposed as markers for major depressive disorder (MDD), but it is not known if or how they change following TMS. METHODS: Resting EEG was obtained from 49 MDD patients at baseline and following six weeks of daily TMS. Polarity-insensitive modified k-means clustering was used to segment EEGs into constituent microstates. Microstates were localized via sLORETA. Repeated-measures mixed models tested for within-subject differences over time and t-tests compared microstate features between TMS responder and non-responder groups. RESULTS: Six microstates (MS-1 - MS-6) were identified from all available EEG data. Clinical response to TMS was associated with increases in features of MS-2, along with decreased metrics of MS-3. Nonresponders showed no significant changes in any microstate. Change in occurrence and coverage of both MS-2 (increased) and MS-3 (decreased) correlated with symptom change magnitude over the course of TMS treatment. CONCLUSIONS: We identified EEG microstates associated with clinical improvement following a course of TMS therapy. Results suggest selective modulation of resting networks observable by EEG, which is inexpensive and easily acquired in the clinic setting.
BACKGROUND: Transcranial magnetic stimulation (TMS) is an effective therapy for patients with treatment-resistant depression. TMS likely induces functional connectivity changes in aberrant circuits implicated in depression. Electroencephalography (EEG) "microstates" are topographies hypothesized to represent large-scale resting networks. Canonical microstates have recently been proposed as markers for major depressive disorder (MDD), but it is not known if or how they change following TMS. METHODS: Resting EEG was obtained from 49 MDD patients at baseline and following six weeks of daily TMS. Polarity-insensitive modified k-means clustering was used to segment EEGs into constituent microstates. Microstates were localized via sLORETA. Repeated-measures mixed models tested for within-subject differences over time and t-tests compared microstate features between TMS responder and non-responder groups. RESULTS: Six microstates (MS-1 - MS-6) were identified from all available EEG data. Clinical response to TMS was associated with increases in features of MS-2, along with decreased metrics of MS-3. Nonresponders showed no significant changes in any microstate. Change in occurrence and coverage of both MS-2 (increased) and MS-3 (decreased) correlated with symptom change magnitude over the course of TMS treatment. CONCLUSIONS: We identified EEG microstates associated with clinical improvement following a course of TMS therapy. Results suggest selective modulation of resting networks observable by EEG, which is inexpensive and easily acquired in the clinic setting.
Authors: Juliana Corlier; Andrew Wilson; Aimee M Hunter; Nikita Vince-Cruz; David Krantz; Jennifer Levitt; Michael J Minzenberg; Nathaniel Ginder; Ian A Cook; Andrew F Leuchter Journal: Cereb Cortex Date: 2019-12-17 Impact factor: 5.357
Authors: Andrew T Drysdale; Logan Grosenick; Jonathan Downar; Katharine Dunlop; Farrokh Mansouri; Yue Meng; Robert N Fetcho; Benjamin Zebley; Desmond J Oathes; Amit Etkin; Alan F Schatzberg; Keith Sudheimer; Jennifer Keller; Helen S Mayberg; Faith M Gunning; George S Alexopoulos; Michael D Fox; Alvaro Pascual-Leone; Henning U Voss; B J Casey; Marc J Dubin; Conor Liston Journal: Nat Med Date: 2016-12-05 Impact factor: 53.440
Authors: Noah S Philip; Jennifer Barredo; Mascha van 't Wout-Frank; Audrey R Tyrka; Lawrence H Price; Linda L Carpenter Journal: Biol Psychiatry Date: 2017-08-08 Impact factor: 13.382
Authors: Shan H Siddiqi; Stephan F Taylor; Danielle Cooke; Alvaro Pascual-Leone; Mark S George; Michael D Fox Journal: Am J Psychiatry Date: 2020-03-12 Impact factor: 18.112
Authors: Andrey Zhdanov; Sravya Atluri; Willy Wong; Yasaman Vaghei; Zafiris J Daskalakis; Daniel M Blumberger; Benicio N Frey; Peter Giacobbe; Raymond W Lam; Roumen Milev; Daniel J Mueller; Gustavo Turecki; Sagar V Parikh; Susan Rotzinger; Claudio N Soares; Colleen A Brenner; Fidel Vila-Rodriguez; Mary Pat McAndrews; Killian Kleffner; Esther Alonso-Prieto; Stephen R Arnott; Jane A Foster; Stephen C Strother; Rudolf Uher; Sidney H Kennedy; Faranak Farzan Journal: JAMA Netw Open Date: 2020-01-03